The proposed mechanisms by which SGLT2 inhibitors improve these HF outcomes include intra‐ and extracellular volume reduction through glucosuria, natriuresis, and osmotic diuresis [5]. The gene discussed is SLC5A2; the disease is hydrops fetalis.